FINWIRES · TerminalLIVE
FINWIRES

KRX:185750

3 stories mentioning KRX:185750Updated 44d ago

Every FINWIRES story that references KRX:185750, newest first.

Asia

Chong Kun Dang Pharmaceutical Confirms KRW2.2 Trillion Biopharma Complex Plan

Chong Kung Dang Pharmaceutical (KRX:185750) reaffirmed its plans for a 2.2 trillion won biopharma R&D complex in Siheung's Baegot district, after it was named a preferred negotiating partner for the site in 2025, according to a Tuesday Korean bourse filing.The company has already approved the acquisition of the land from Siheung City for 94.9 billion won, with the final payment to be completed on Aug. 18.

KRX:185750
Asia

South Korean Shares Extend Rally as Reopening of Strait of Hormuz Boosts Sentiment

South Korean markets extended their rally for a fourth consecutive session on Tuesday, driven by investor optimism following a landmark agreement between the U.S. and Iran to end hostilities and reopen the Strait of Hormuz.The benchmark Korea Composite Stock Price Index, or Kospi, increased by 2.1%, or 180.62 points, to close at 8,726.6. The Kosdaq decreased by 1.5%, or 15.35 points, to end at 1,018.68.In economic news, South Korea's export prices surged 46.9% year over year in May, while import prices increased 24.8%, according to preliminary data released by the Bank of Korea on Tuesday.The net barter terms of trade index rose 18.7% in May from the same period last year.In corporate news, Chong Kun Dang Pharmaceutical (KRX:185750) plans to invest a total of 392.5 billion won to build a research and demonstration center for biopharmaceutical research and development in Baegot-dong, Siheung-si, according to a Tuesday filing with the Korea Exchange.The investment will be made from June 11, 2026, to Aug. 31, 2028.Shares of Chong Kun Dang Pharmaceutical rose more than 3% at market close.

^KOSDAQKOSPIKRX:185750
Asia

Chong Kun Dang Pharmaceutical to Invest KRW392.5 Billion in Biopharmaceutical R&D Center

Chong Kun Dang Pharmaceutical (KRX:185750) plans to invest a total of 392.5 billion won to build a research and demonstration center for biopharmaceutical research and development in Baegot-dong, Siheung-si, according to a Tuesday filing with the Korea Exchange.The investment will be made from June 11, 2026, to Aug. 31, 2028.Shares of Chong Kun Dang Pharmaceutical rose more than 2% in recent trade.

KRX:185750

Track with the FINWIRES app suite